Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,265
archived clinical trials in
Rheumatoid Arthritis

COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Reno, NV
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Reno, NV
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Dover, NH
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Dover, NH
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Berlin, NJ
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Berlin, NJ
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Mercerville, NJ
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Mercerville, NJ
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Johnson City, NY
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Johnson City, NY
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Kingston, NY
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Kingston, NY
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
New York, NY
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
North Massapequa, NY
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
North Massapequa, NY
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Rochester, NY
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Rochester, NY
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Charlotte, NC
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Gastonia, NC
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Gastonia, NC
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Hickory, NC
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Hickory, NC
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Statesville, NC
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Statesville, NC
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Cleveland, OH
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Cleveland, OH
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Columbus, OH
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Columbus, OH
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Concinnati, OH
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Concinnati, OH
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Mayfield Village, OH
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Mayfield Village, OH
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Oklahoma City, OK
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Tulsa, OK
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Tulsa, OK
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Medford, OR
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Medford, OR
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Duncansville, PA
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Duncansville, PA
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Philadelphia, PA
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
West Reading, PA
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
West Reading, PA
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Charleston, SC
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Greer, SC
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Greer, SC
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Hampton, SC
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Hampton, SC
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Murrells Inlet, SC
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Murrells Inlet, SC
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Memphis, TN
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Memphis, TN
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Austin, TX
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Dallas, TX
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
San Antonio, TX
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Everett, WA
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Everett, WA
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Vancouver, WA
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Vancouver, WA
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Racine, WI
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Racine, WI
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Cordoba,
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Cordoba,
Click here to add this to my saved trials
(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients With Active Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).
Status: Enrolling
Updated:  4/26/2017
Santarus Clinical Investigational Site 1012
mi
from
Phoenix, AZ
(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients With Active Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).
Status: Enrolling
Updated: 4/26/2017
Santarus Clinical Investigational Site 1012
mi
from
Phoenix, AZ
Click here to add this to my saved trials
(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients With Active Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).
Status: Enrolling
Updated:  4/26/2017
Santarus Clinical Investigational Site 1004
mi
from
El Cajon, CA
(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients With Active Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).
Status: Enrolling
Updated: 4/26/2017
Santarus Clinical Investigational Site 1004
mi
from
El Cajon, CA
Click here to add this to my saved trials
(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients With Active Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).
Status: Enrolling
Updated:  4/26/2017
Santarus Clinical Investigational Site 1051
mi
from
Los Angeles, CA
(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients With Active Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).
Status: Enrolling
Updated: 4/26/2017
Santarus Clinical Investigational Site 1051
mi
from
Los Angeles, CA
Click here to add this to my saved trials
(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients With Active Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).
Status: Enrolling
Updated:  4/26/2017
Santarus Clinical Investigational Site 1011
mi
from
San Leandro, CA
(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients With Active Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).
Status: Enrolling
Updated: 4/26/2017
Santarus Clinical Investigational Site 1011
mi
from
San Leandro, CA
Click here to add this to my saved trials
(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients With Active Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).
Status: Enrolling
Updated:  4/26/2017
Santarus Clinical Investigational Site 1013
mi
from
Brandon, FL
(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients With Active Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).
Status: Enrolling
Updated: 4/26/2017
Santarus Clinical Investigational Site 1013
mi
from
Brandon, FL
Click here to add this to my saved trials
(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients With Active Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).
Status: Enrolling
Updated:  4/26/2017
Santarus Clinical Investigational Site 1003
mi
from
Palm Harbor, FL
(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients With Active Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).
Status: Enrolling
Updated: 4/26/2017
Santarus Clinical Investigational Site 1003
mi
from
Palm Harbor, FL
Click here to add this to my saved trials
(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients With Active Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).
Status: Enrolling
Updated:  4/26/2017
Santarus Clinical Investigational Site 1017
mi
from
Florissant, MO
(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients With Active Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).
Status: Enrolling
Updated: 4/26/2017
Santarus Clinical Investigational Site 1017
mi
from
Florissant, MO
Click here to add this to my saved trials
(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients With Active Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).
Status: Enrolling
Updated:  4/26/2017
Santarus Clinical Investigational Site 1009
mi
from
Brooklyn, NY
(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients With Active Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).
Status: Enrolling
Updated: 4/26/2017
Santarus Clinical Investigational Site 1009
mi
from
Brooklyn, NY
Click here to add this to my saved trials
(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients With Active Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).
Status: Enrolling
Updated:  4/26/2017
Santarus Clinical Investigational Site 1019
mi
from
Chapel Hill, NC
(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients With Active Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).
Status: Enrolling
Updated: 4/26/2017
Santarus Clinical Investigational Site 1019
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients With Active Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).
Status: Enrolling
Updated:  4/26/2017
Santarus Clinical Investigational Site 1014
mi
from
Charlotte, NC
(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients With Active Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).
Status: Enrolling
Updated: 4/26/2017
Santarus Clinical Investigational Site 1014
mi
from
Charlotte, NC
Click here to add this to my saved trials
(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients With Active Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).
Status: Enrolling
Updated:  4/26/2017
Santarus Clinical Investigational Site 1006
mi
from
Salisbury, NC
(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients With Active Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).
Status: Enrolling
Updated: 4/26/2017
Santarus Clinical Investigational Site 1006
mi
from
Salisbury, NC
Click here to add this to my saved trials
(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients With Active Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).
Status: Enrolling
Updated:  4/26/2017
Santarus Clinical Investigational Site 1001
mi
from
Middleburg Heights, OH
(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients With Active Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).
Status: Enrolling
Updated: 4/26/2017
Santarus Clinical Investigational Site 1001
mi
from
Middleburg Heights, OH
Click here to add this to my saved trials
Study of Adalimumab to Lower Cardiovascular Risk in RA Patients With Well Controlled Joint Disease
Adalimumab to Mitigate Cardiovascular Risk in RA Patients With Well-Controlled Joint Disease
Status: Enrolling
Updated:  5/1/2017
University of California, San Francisco, San Francisco General Hospital
mi
from
San Francisco, CA
Study of Adalimumab to Lower Cardiovascular Risk in RA Patients With Well Controlled Joint Disease
Adalimumab to Mitigate Cardiovascular Risk in RA Patients With Well-Controlled Joint Disease
Status: Enrolling
Updated: 5/1/2017
University of California, San Francisco, San Francisco General Hospital
mi
from
San Francisco, CA
Click here to add this to my saved trials
Causes of Comorbid Infertility Among Women With Rheumatoid Arthritis
Causes of Comorbid Infertility Among Women With Rheumatoid Arthritis
Status: Enrolling
Updated:  5/3/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Causes of Comorbid Infertility Among Women With Rheumatoid Arthritis
Causes of Comorbid Infertility Among Women With Rheumatoid Arthritis
Status: Enrolling
Updated: 5/3/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Safety and Effectiveness Study of the Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE)
Safety and Effectiveness Study of the Live Zoster Vaccine in Anti-TNF Users (VERVE)
Status: Enrolling
Updated:  5/4/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Safety and Effectiveness Study of the Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE)
Safety and Effectiveness Study of the Live Zoster Vaccine in Anti-TNF Users (VERVE)
Status: Enrolling
Updated: 5/4/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials